Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Toonaangevende leiders

HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van bedrijfsleiders 
Portrait de Milind S. Deshpande
Leeftijd : 65
Vermogen : 61 650 USD
Belangrijkste bedrijven : Spero Therapeutics, Inc.
Overzicht 
Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development.

He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience.

He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences.

He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Milind attended the residential Executive Program at The Wharton School of Management.


Posities en verantwoordelijkheden van Milind S. Deshpande 
NaamTitel Van
Spero Therapeutics, Inc.
(Biotechnologie & Medisch Onderzoek)
Chairman -
Clear Creek Bio, Inc. Board Member 2020
Nayan Therapeutics, Inc. President, Chief Executive Officer & Director 2019
Santi Therapeutics, Inc. Chief Executive Officer & Board Member 2019
Avilar Therapeutics, Inc. Chairman 2021
RA Capital Management LP (Private Equity) Venture Partner 2018


Belangnemingen van Milind S. Deshpande 
NaamAandelen%Totale waarde
Spero Therapeutics, Inc. (SPRO)
(Biotechnologie & Medisch Onderzoek)
31 4540,090%61 650 USD


Milind S. DeshpandePersoonlijk netwerk 
Meest gelezen nieuws 
21/11Buffett's Berkshire vergroot belangen in vijf grootste Japanse handelshuizen
MR
01/12Salesforce-aandelen tuimelen na verrassende exit van mede-CEO Taylor
MR
23/11Berkshire Hathaway zegt dat Warren Buffett aandelen schenkt aan goede doelen in de familie
MR
30/11Meta's Zuckerberg zegt dat sommige van Elon Musks Twitter-contentaanpak 'zou kunnen werken'.
MR
30/11Juventus heeft geen behoefte aan extra kapitaal, zegt Elkann van Exor
MR
22/11Boomerang CEO's' werken niet altijd; Disney hoopt dat deze CEO de trend doorbreekt.
MR
22/11Musk zegt dat Twitter de herlancering van blue check-verificatie uitstelt
MR
20/11Musk's Twitter poll laat zien dat krappe meerderheid Trump opnieuw wil laten optreden
MR
29/11O'Leary van Ryanair noemt sector meest optimistisch in 25 jaar
MR
29/11Prada neemt voormalig Luxottica CEO Guerra in dienst om opvolging te vergemakkelijken - bron
MR
Meer nieuws


© 2022 People and Ownership :   
Milind S. Deshpande Verbindingen